CN103910719B - 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 - Google Patents
葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 Download PDFInfo
- Publication number
- CN103910719B CN103910719B CN201210594547.XA CN201210594547A CN103910719B CN 103910719 B CN103910719 B CN 103910719B CN 201210594547 A CN201210594547 A CN 201210594547A CN 103910719 B CN103910719 B CN 103910719B
- Authority
- CN
- China
- Prior art keywords
- compound
- phenylalanine
- eutectic crystal
- preparation
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 104
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title abstract description 18
- -1 phenylalanine compound Chemical class 0.000 title abstract description 9
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 92
- 230000005496 eutectics Effects 0.000 claims abstract description 87
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims abstract description 7
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 claims abstract description 4
- 108091052347 Glucose transporter family Proteins 0.000 claims abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 230000007850 degeneration Effects 0.000 claims abstract description 3
- 208000024891 symptom Diseases 0.000 claims abstract description 3
- 229940126062 Compound A Drugs 0.000 claims description 65
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 65
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 39
- 229960005190 phenylalanine Drugs 0.000 claims description 31
- 238000013019 agitation Methods 0.000 claims description 29
- 238000001816 cooling Methods 0.000 claims description 20
- 235000008729 phenylalanine Nutrition 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 239000004677 Nylon Substances 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- 229920001778 nylon Polymers 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 229910017488 Cu K Inorganic materials 0.000 claims description 7
- 229910017541 Cu-K Inorganic materials 0.000 claims description 7
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 2
- 230000009514 concussion Effects 0.000 claims description 2
- 239000012982 microporous membrane Substances 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical group CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 abstract description 3
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 2
- 150000002994 phenylalanines Chemical class 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 35
- 239000000243 solution Substances 0.000 description 35
- 206010001497 Agitation Diseases 0.000 description 28
- 239000002994 raw material Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 238000003760 magnetic stirring Methods 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- 108091006269 SLC5A2 Proteins 0.000 description 4
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 description 4
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000010287 polarization Effects 0.000 description 4
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropyl alcohol Natural products CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 3
- 108091006277 SLC5A1 Proteins 0.000 description 3
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 0 CC(C[C@@](C(O)=*)N)=CC=CC=I Chemical compound CC(C[C@@](C(O)=*)N)=CC=CC=I 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 150000008547 L-phenylalanines Chemical class 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
峰位数字标注 | 2θ值 | 峰位数字标注 | 2θ值 |
1 | 11.233 | 13 | 22.455 |
2 | 11.72 | 14 | 23.627 |
3 | 12.443 | 15 | 24.04 |
4 | 14.514 | 16 | 24.937 |
5 | 16.805 | 17 | 26.01 |
6 | 17.389 | 18 | 28.083 |
7 | 18.062 | 19 | 28.907 |
8 | 18.781 | 20 | 29.752 |
9 | 19.942 | 21 | 30.147 |
10 | 20.188 | 22 | 31.78 |
11 | 20.75 | 23 | 33.668 |
12 | 21.841 | 24 | 36.472 |
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210594547.XA CN103910719B (zh) | 2012-12-31 | 2012-12-31 | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210594547.XA CN103910719B (zh) | 2012-12-31 | 2012-12-31 | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103910719A CN103910719A (zh) | 2014-07-09 |
CN103910719B true CN103910719B (zh) | 2018-05-01 |
Family
ID=51036769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210594547.XA Expired - Fee Related CN103910719B (zh) | 2012-12-31 | 2012-12-31 | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103910719B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106892948B (zh) * | 2015-12-17 | 2022-07-26 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物及其在医药上的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101238112A (zh) * | 2005-09-08 | 2008-08-06 | 贝林格尔·英格海姆国际有限公司 | 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途 |
CN101479287A (zh) * | 2006-06-28 | 2009-07-08 | 布里斯托尔-迈尔斯斯奎布公司 | 作为用于治疗糖尿病的sglt2抑制剂的(1s)-1,5-脱水-l-c-(3-((苯基)甲基)苯基)-d-葡萄糖醇衍生物与氨基酸的结晶溶剂合物和络合物 |
CN102149280A (zh) * | 2008-07-15 | 2011-08-10 | 泰拉科斯有限公司 | 氘化苄基苯衍生物及其使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101754972A (zh) * | 2007-05-18 | 2010-06-23 | 百时美施贵宝公司 | Sglt2抑制剂的晶体结构及其制备方法 |
ME02702B (me) * | 2008-08-22 | 2017-10-20 | Theracos Sub Llc | Postupci za pripremu inhibitora sgl t2 |
WO2012109996A1 (zh) * | 2011-02-18 | 2012-08-23 | 上海璎黎科技有限公司 | 一种芳基糖苷类化合物及其制备方法和应用 |
-
2012
- 2012-12-31 CN CN201210594547.XA patent/CN103910719B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101238112A (zh) * | 2005-09-08 | 2008-08-06 | 贝林格尔·英格海姆国际有限公司 | 1-氯-4-(β-D-吡喃葡萄糖-1-基)-2-(4-乙炔基-苄基)-苯的晶形、其制备方法及其用于制备药物中的用途 |
CN101479287A (zh) * | 2006-06-28 | 2009-07-08 | 布里斯托尔-迈尔斯斯奎布公司 | 作为用于治疗糖尿病的sglt2抑制剂的(1s)-1,5-脱水-l-c-(3-((苯基)甲基)苯基)-d-葡萄糖醇衍生物与氨基酸的结晶溶剂合物和络合物 |
CN102149280A (zh) * | 2008-07-15 | 2011-08-10 | 泰拉科斯有限公司 | 氘化苄基苯衍生物及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103910719A (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014532639A (ja) | Sglt2阻害剤の結晶および非結晶形態 | |
CN102875574A (zh) | 头孢曲松钠晶型及其制备方法 | |
CN101671314B (zh) | 一种非布索坦的晶型体及制备方法 | |
CN102516096B (zh) | 一种盐酸氨溴索化合物的精制法 | |
CN104887673B (zh) | 一种含埃索美拉唑钠的药物组合物及其制备方法 | |
CN103910769B (zh) | 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用 | |
CN102875531B (zh) | 一种(r)-兰索拉唑无水晶型及其制备方法 | |
CN105693624B (zh) | 马西替坦晶体及其制备方法、其药物组合物和用途 | |
CN105434362B (zh) | 高纯度颗粒型盐酸氨丙啉的制备方法 | |
CN102250165A (zh) | 一种春雷霉素原药制备方法 | |
CN103012430A (zh) | 美洛西林钠化合物及其药物组合物 | |
CN103965116A (zh) | 半5-氟胞嘧啶盐、其制备方法及应用 | |
CN103910719B (zh) | 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用 | |
CN104961749B (zh) | 一种头孢呋辛钠的新型工业结晶方法及其制剂 | |
CN102643255A (zh) | 一种炎琥宁化合物 | |
CN106966944A (zh) | 一种维格列汀晶型化合物及其制备方法 | |
EP3453712B1 (en) | Diethylamine solvate of sodium-glucose linked transporter inhibitor, and preparation method and application thereof | |
CN102875532B (zh) | 一种(r)-兰索拉唑异丙胺盐及其晶型和制备方法 | |
CN106831709B (zh) | 右旋兰索拉唑-异烟碱共晶及其应用 | |
CN106866631A (zh) | 一种右旋兰索拉唑晶型及制备方法 | |
CN100372858C (zh) | 一种精制奥沙利铂的方法 | |
CN102442990A (zh) | 一种金雀异黄素烟酰胺共晶、其晶体及其制备方法 | |
Hu et al. | Effects of Tween-80 on the dissolution properties of daidzein solid dispersion in vitro | |
CN102875530A (zh) | 一种(r)-兰索拉唑叔丁胺盐及其晶型和制备方法 | |
EP4122909A1 (en) | Crystal form of aromatic vinyl derivatives, and preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201203 Shanghai Guo Shou Jing Road, Zhangjiang High Tech Park of Pudong New Area traditional Chinese medicine No. 199 building room 109 Applicant after: SHANGHAI YINGLI PHARMACEUTICAL Co.,Ltd. Address before: 201203 Shanghai Guo Shou Jing Road, Zhangjiang High Tech Park of Pudong New Area traditional Chinese medicine No. 199 building room 109 Applicant before: SHANGHAI YINGLI SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210825 Address after: 226241 No. 1, dongzhenhai Road, Binhai Industrial Park, lvsigang Economic Development Zone, Qidong, Nantong, Jiangsu Patentee after: Shanghua Kechuang Investment Management (Jiangsu) Co.,Ltd. Address before: Room 109, traditional Chinese medicine building, 199 GuoShouJing Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai 201203 Patentee before: SHANGHAI YINGLI PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180501 |